[8],[53-55] Therefore, the inclusion of GLP-1RA or SGLT2i at the time of diagnosis of T2D in patients with ASCVD or multiple risk factors is a reasonable option and aligns with the views of Diabetes Canada
3rd GLP-1 Based Therapeutics Summit 2026 14th April 2026 - April 16, 2026 The 3rd GLP-1 Based Therapeutics Summit is the essential industry forum dedicated to solving the critical challenges of GLP-1 combinations, mastering tolerability, drug delivery, and seizing the multi-billion dollar opportunity in non-obesity indications
Most people are on the medication for many months, often more than a year, so the realistic budgeting horizon is the cumulative cost across the planned duration, not just the first month
2,13 In more severe cases, complications such as gastroparesis, pancreatitis, and GI bleeding may occur
Of the 1822 participants on a GLP-1 RA, 72% (1309 individuals) were still on therapy for at least 3 years